methyphenidate
PreclinicalSmall molecule
methyphenidate is one of 32 small molecule programs targeting Weight loss. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Weight Loss
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Ozempic
Novo NordiskApproved
Farxiga
AstraZenecaApproved
Glucophage
EMD SeronoApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Topamax
WWim Janssens
Approved
Xifaxan
SSalix
Approved
Invokana
WWim Janssens
Approved
Megace
Bristol-Myers SquibbPhase 3
Versed
CConrado Roberto Hoffmann Filho
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for methyphenidate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIRCCS Eugenio Medea